508 related articles for article (PubMed ID: 29792136)
21. Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?
Rajasekeran H; Cherney DZ; Lovshin JA
Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):358-367. PubMed ID: 28582367
[TBL] [Abstract][Full Text] [Related]
22. Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials.
Chewcharat A; Takkavatakarn K; Isaranuwatchai S; Katavetin P; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
Int Urol Nephrol; 2020 Sep; 52(9):1733-1745. PubMed ID: 32524495
[TBL] [Abstract][Full Text] [Related]
23. Sodium-glucose Cotransporter Type 2 Inhibitors: A New Insight into the Molecular Mechanisms of Diabetic Nephropathy.
Li N; Zhou H
Curr Pharm Des; 2022; 28(26):2131-2139. PubMed ID: 35718973
[TBL] [Abstract][Full Text] [Related]
24. The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes.
Gillard P; Schnell O; Groop PH
Diabetes Res Clin Pract; 2020 Dec; 170():108462. PubMed ID: 32971152
[TBL] [Abstract][Full Text] [Related]
25. Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.
Warren AM; Knudsen ST; Cooper ME
Expert Opin Ther Targets; 2019 Jul; 23(7):579-591. PubMed ID: 31154867
[No Abstract] [Full Text] [Related]
26. SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.
Imprialos K; Faselis C; Boutari C; Stavropoulos K; Athyros V; Karagiannis A; Doumas M
Curr Pharm Des; 2017; 23(10):1510-1521. PubMed ID: 28120716
[TBL] [Abstract][Full Text] [Related]
27. Diabetic proximal tubulopathy: Can we mimic the disease for in vitro screening of SGLT inhibitors?
Faria J; Gerritsen KGF; Nguyen TQ; Mihaila SM; Masereeuw R
Eur J Pharmacol; 2021 Oct; 908():174378. PubMed ID: 34303664
[TBL] [Abstract][Full Text] [Related]
28. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
Scheen AJ
Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
[TBL] [Abstract][Full Text] [Related]
29. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells.
Maki T; Maeno S; Maeda Y; Yamato M; Sonoda N; Ogawa Y; Wakisaka M; Inoguchi T
Sci Rep; 2019 Mar; 9(1):4703. PubMed ID: 30886225
[TBL] [Abstract][Full Text] [Related]
30. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
31. The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.
Lioudaki E; Androulakis ES; Whyte M; Stylianou KG; Daphnis EK; Ganotakis ES
Cardiovasc Drugs Ther; 2017 Apr; 31(2):215-225. PubMed ID: 28444472
[TBL] [Abstract][Full Text] [Related]
32. Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors-is hemodynamics the key point?
Lee B; Holstein-Rathlou NH; Sosnovtseva O; Sørensen CM
Am J Physiol Cell Physiol; 2023 Jul; 325(1):C243-C256. PubMed ID: 37273240
[TBL] [Abstract][Full Text] [Related]
33. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms.
Kashihara N; Kidokoro K; Kanda E
Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):112-118. PubMed ID: 31725011
[TBL] [Abstract][Full Text] [Related]
34. New Glucose-Lowering Agents for Diabetic Kidney Disease.
de Vos LC; Hettige TS; Cooper ME
Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579
[TBL] [Abstract][Full Text] [Related]
35. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus.
Kumar S; Khatik GL; Mittal A
Mini Rev Med Chem; 2020; 20(3):170-182. PubMed ID: 32134370
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease.
Østergaard MV; Secher T; Christensen M; Salinas CG; Roostalu U; Skytte JL; Rune I; Hansen HH; Jelsing J; Vrang N; Fink LN
Am J Physiol Renal Physiol; 2021 Aug; 321(2):F149-F161. PubMed ID: 34180715
[TBL] [Abstract][Full Text] [Related]
37. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
[TBL] [Abstract][Full Text] [Related]
38. The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice.
Li Z; Murakoshi M; Ichikawa S; Koshida T; Adachi E; Suzuki C; Ueda S; Gohda T; Suzuki Y
FEBS Open Bio; 2020 Dec; 10(12):2761-2770. PubMed ID: 33098615
[TBL] [Abstract][Full Text] [Related]
39. Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists.
Prattichizzo F; de Candia P; Ceriello A
Metabolism; 2021 Jul; 120():154799. PubMed ID: 34029597
[TBL] [Abstract][Full Text] [Related]
40. Renal SGLT mRNA expression in human health and disease: a study in two cohorts.
Srinivasan Sridhar V; Ambinathan JPN; Kretzler M; Pyle LL; Bjornstad P; Eddy S; Cherney DZ; Reich HN; ;
Am J Physiol Renal Physiol; 2019 Nov; 317(5):F1224-F1230. PubMed ID: 31545924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
